Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hyperfractionated Accelerated Radiotherapy (HART) With Chemotherapy (Cisplatin, CCNU, Vincristine) for Metastatic (M1-3) Medulloblastoma

NCT00276666 is registered in ClinicalTrials.gov with Children's Cancer and Leukaemia Group as lead sponsor.

NCT NCT00276666
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00276666 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hyperfractionated Accelerated Radiotherapy (HART) With Chemotherapy (Cisplatin, CCNU, Vincristine) for Metastatic (M1-3) Medulloblastoma
Lead sponsor
Children's Cancer and Leukaemia Group
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2001
Completion date
Not reported
Enrollment
29 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors